Skip to main content
. 2023 Dec 31;28(1):30–35. doi: 10.5005/jp-journals-10071-24595

Table 2.

Details of the dialysis treatments for the patients with SA-AKI studied

Characteristic features SLED group (n = 31) CRRT group (n = 22) Total (n = 53) p-value
*Main indications for dialysis 0.34
 Pulmonary edema 18 (58.1%) 6 (27.3%) 24 (45.3%)
 Urea levels > 250 mg/dL 14 (45.2%) 8 (36.4%) 22 (41.5%)
 Severe metabolic acidosis 8 (25.8%) 10 (45.5%) 18 (34%)
 Anuria 10 (32.3%) 6 (27.3%) 16 (30.2%)
 Resistant hyperkalemia 4 (12.9%) 4 (18.2%) 8 (15.1%)
Delivered dialysis therapy
 Total number of sessions delivered 91 (72.8%) 34 (27.2%) 125 (100%) <0.001
 Mean dialysis duration (hour/session) 6.9 ± 1.6 41.6 ± 6.9 <0.001
 Mean blood flow (mL/minute) 209.4 ± 32.7 98.3 ± 51.2 <0.001
 Mean dialysate flow (mL/minute) 218.4 ± 31.8
 Mean effluent flow (m/kg/hour) 26.4 ± 13.2
 Mean net ultrafiltration (L/session) 1.4 ± 0.7 3.5 ± 0.9 <0.001
 Heparin anticoagulation given 29 (93.5%) 21 (95.5%) 50 (94.3%) 0.77
*Dialysis complications necessitated withholding of therapy 0.19
 Persistent hypotension 16 (51.6%) 12 (54.5%) 28 (52.8%)
 Persistent hypoglycemia 10 (32.3%) 4 (18.2%) 14 (26.4%)
 Cardiac arrest 3 (9.7%) 5 (22.7%) 8 (15.1%)
 Cardiac arrhythmias 1 (3.2%) 3 (13.6%) 4 (7.5%)
 Bleeding 0 (0%) 1 (4.5%) 1 (1.9%)
 Recurrent hypokalemia 0 (0%) 2 (9.1%) 2 (3.8%)

Data are presented as means ± SD or n (%). *An overlap in these features does occur. CRRT, continuous renal replacement therapy; SLED, sustained low-efficiency dialysis